KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Income: 2010-2025

Historic Net Income for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $51.2 million.

  • Emergent BioSolutions' Net Income fell 55.40% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 136.35%. This contributed to the annual value of -$190.6 million for FY2024, which is 74.94% up from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Net Income is $51.2 million, which was up 526.67% from -$12.0 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Net Income peaked at $177.9 million during Q4 2021, and registered a low of -$283.1 million during Q2 2024.
  • Its 3-year average for Net Income is -$76.7 million, with a median of -$31.3 million in 2024.
  • Per our database at Business Quant, Emergent BioSolutions' Net Income spiked by 657.60% in 2021 and then slumped by 4,932.43% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Net Income (Quarterly) stood at $177.9 million in 2021, then slumped by 137.66% to -$67.0 million in 2022, then climbed by 26.12% to -$49.5 million in 2023, then spiked by 36.77% to -$31.3 million in 2024, then slumped by 55.40% to $51.2 million in 2025.
  • Its last three reported values are $51.2 million in Q3 2025, -$12.0 million for Q2 2025, and $68.0 million during Q1 2025.